CHRS
Coherus Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.42
+3.65%Aug 17, 2026, 21:33 UTC
Coherus Oncology announced a special dividend of contingent value rights (CVRs) to its stockholders, entitling them to net proceeds from the sale of its remaining legacy biosimilar assets.
Aug 17, 2026, 00:00 UTC
Coherus Oncology, Inc. entered into a new $55 million senior secured term loan facility with Innovatus Life Sciences Lending Fund I, LP, fully drawing the Tranche A amount on August 14, 2026, to repay its prior term loan and for working capital.
Aug 5, 2026, 23:11 UTC
Coherus Oncology reported a Q2 2026 loss of $0.19 per share, missing the Zacks Consensus Estimate of $0.08 per share.
Jun 15, 2026, 00:00 UTC
Coherus Oncology, Inc. dismissed Ernst & Young LLP as its independent registered public accounting firm and appointed PricewaterhouseCoopers LLP as its new auditor, effective June 12, 2026.